Table 5.
Toxicity of Chemoimmunotherapy per Patient
| CTC Grade 3/4 | Qualifying for Radiotherapy (n = 467) | Not Qualifying for Radiotherapy (n = 228) | ||||
|---|---|---|---|---|---|---|
| R-CHOP-21 (n = 81) |
R-CHOP-14 (n = 81) |
R-CHOP-21 + Radiotherapy (n = 155) |
R-CHOP-14 + Radiotherapy (n = 150) |
R-CHOP-21 (n = 114) |
R-CHOP-14 (n = 114) |
|
| Leukocytopeniaa | 31/43 72% |
22/44 50% |
45/76 59% |
36/83 43% |
21/49 43% |
21/55 38% |
| Thrombocytopenia | 3/76 4% |
3/75 4% |
3/142 2% |
0/137 0% |
2/99 2% |
1/103 1% |
| Anemia | 1/76 1% |
3/76 4% |
9/145 6% |
10/136 7% |
2/100 2% |
11/104 11% |
| Arrhythmia | 0/75 (0%) |
0/74 (0%) |
0/149 (0%) | 2/141 (1%) | 2/105 (2%) | 0/112 (0%) |
| Cardiac functions | 0/73 (0%) |
0/72 (0%) |
1/149 (1%) | 2/138 (1%) | 0/105 (0%) | 0/112 (0%) |
| Sensory | 3/75 (4%) |
4/76 (5%) |
10/150 (6%) | 4/141 (3%) | 3/103 (3%) | 8/111 (7%) |
| Infection | 6/79 (8%) |
12/78 (15%) | 13/152 (9%) | 15/144 (10%) | 8/105 (8%) | 12/113 (11%) |
Remark: Nonhematological toxicities are outlined if observed in 5% of patients or more. Cardiac toxicity is outlined additionally.
aBased on the blood counts within nadir interval day 11–14 (R-CHOP-21) and day 8–10 (R-CHOP-14).
CTC = common toxicity criteria; R-CHOP = rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone.